Table 2.
Laboratory data in patients with APE confirmed and excluded
| Normal range missing data (n) | All patients (n = 41) | APE confirmed (n = 8) | APE excluded (n = 33) | P‐value (APE confirmed vs excluded) | |
|---|---|---|---|---|---|
| d‐Dimer, median (IQR) (μg/mL) | 0–243 (0) | 1488 (446–4211) | 3236 (1943–4735) | 1056 (446–2634) | 0.316 |
| INR, median (IQR) | 0.8–1.2 (9) | 1.2 (1.1–1.3) | 1.2 (1.1–1.2) | 1.2 (1.1–1.3) | 0.749 |
| Albumin, median (IQR) (g/dL) | 3.7–5.3 (10) | 3.0 (2.9–3.3) | 2.7 (2.4–3.1) | 3.1 (3–3.3) | 0.284 |
| CRP, median (IQR) (mg/dL) | 0.0–8.0 (0) | 51 (18–140) | 67 (40.2–157.8) | 50 (16–135) | 0.439 |
| WBCC, median (IQR) (×109/L) | 4.0–11.0 (0) | 9.1 (7–12.2) | 12.4 (10.4–13.4) | 8.4 (6.4–10.5) | 0.007 |
| LDH, median (IQR) (U/L) | 135–225 (1) | 332 (251.8–419.2) | 330 (249.2–340.8) | 354.5 (251.8–441.8) | 0.437 |
| ALT, median (IQR) (U/L) | 5–43 (1) | 41 (27.8–53.2) | 34.5 (23–39) | 44.5 (28.8–55) | 0.058 |
| AST, median (IQR) (U/L) | 3–45 (0) | 43.5 (30.8–70) | 44 (28–58.2) | 43.5 (30.8–73.2) | 0.488 |
| Cr, median (IQR) (μmol/L) | 0.6–1.2 (0) | 0.9 (0.8–1) | 0.9 (0.8–1.1) | 0.8 (0.8–1) | 0.383 |
| Interleukin 6, median (IQR) (pg/mL) | <7 (15) | 11.9 (7.8–38.7) | 20.8 (10.6–37.8) | 11.6 (7–35.9) | 0.287 |
| Antithrombin III, median (IQR) | 80–120 (19) | 100.5 (90.2–114.2) | 89 (88–103) | 102 (95–115) | 0.456 |
| PaCO2, median (IQR) (mmHg) | 32–45 (0) | 37 (34–42) | 42 (38–43.2) | 36 (34–39) | 0.171 |
| PaO2, median (IQR) (mmHg) | 83–108 (0) | 95 (71–143) | 129 (65.2–146.2) | 91 (71–139) | 0.934 |
| PaO2/FiO2 ratio, median (IQR) | >350 (0) | 123 (93–186) | 161 (127.8–195.8) | 117 (93–174) | 0.633 |
ALT, alanine aminotransferase; APE, acute pulmonary embolism; AST, aspartate transaminase; Cr, creatinine; CRP, C‐reactive protein; FiO2, fraction of inspired oxygen; INR, international normalised ratio; IQR, interquartile range; LDH, lactate dehydrogenase; PaCO2, arterial partial pressure of carbon dioxide; PaO2,arterial oxygen partial pressure; WBCC, white blood cell count.